{"filing":{"accession_number":"0001213900-26-088701","cik":"0001704287","ticker":"BJDX","company_name":"Bluejay Diagnostics, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"ea0301888-8k_bluejay.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026088701/ea0301888-8k_bluejay.htm"},"events":[{"id":27521,"run_id":25092,"accession_number":"0001213900-26-088701","anchor_item_number":"7.01","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Bluejay Diagnostics disclosed Q2 2026 financial results for the quarter ended June 30, 2026, reporting a cash position of $9.6 million at quarter-end (versus $5.2 million at year-end 2025) and $7.7 million net cash from financing activities in H1 2026, along with operational progress on the Symphony IL-6 platform.","company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29099,"accession_number":"0001213900-26-088701","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses Q2 2026 financial results for the quarter ended June 30, 2026, including cash position ($9.6 million at quarter-end vs. $5.2 million at year-end 2025) and financing activities ($7.7 million net cash from financing in H1 2026). While the press release emphasizes clinical and regulatory progress on the Symphony IL-6 platform, it is fundamentally a quarterly financial and business update issued following the 10-Q filing, meeting the definition of an earnings release disclosure under Item 7.01 (Regulation FD Disclosure).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:57:41.310819+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29099,"accession_number":"0001213900-26-088701","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses Q2 2026 financial results for the quarter ended June 30, 2026, including cash position ($9.6 million at quarter-end vs. $5.2 million at year-end 2025) and financing activities ($7.7 million net cash from financing in H1 2026). While the press release emphasizes clinical and regulatory progress on the Symphony IL-6 platform, it is fundamentally a quarterly financial and business update issued following the 10-Q filing, meeting the definition of an earnings release disclosure under Item 7.01 (Regulation FD Disclosure).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:57:41.310819+00:00","company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","filing_date":"2026-08-13"}]}